Winton Matthew Insider Profile
11 Followers
Winton Matthew, Chief Commercial and Business at CervoMed, holds 15.00K shares in CervoMed (Ticker: CRVO), holds 0.00 shares in Inozyme Pharma (Ticker: INZY). Most recently, Winton Matthew Bought ― shares of CervoMed on Nov 19, 2025 for an estimated value of $41.43K.
Winton Matthew CervoMed (CRVO)Chief Commercial and Business
CervoMed (CRVO)
Chief Commercial and Business
Ranked #95,992 out of 108,921 Corporate Insiders
Profitable Transactions
0 out of 2 Profitable Transactions
Average Return
-69.50%
Average return per transaction
Time Frame
Compare to
Insider Roles
Chief Commercial and Business
Roles that Winton Matthew holds in companies
Most Profitable Insider Trade
The most profitable trade made by Winton Matthew
Winton Matthew's Trading History
CervoMed
Nov 19, 2025
Chief Commercial and Business
Informative Buy
41.43K
$38.40K
Inozyme Pharma
Jul 03, 2025
―
Uninformative Sell
86.97K
$0.00
List of latest transactions for each holding click on a transaction to see Winton Matthew's performance on stock
You May Also Like
Winton Matthew insider profile FAQ
What is the percentage of profitable transactions made by Winton Matthew?
The percentage of profitable transactions made by Winton Matthew is 0%.
What is the average return per transaction made by Winton Matthew?
The average return per transaction made by Winton Matthew is -69.50%.
What stocks does Winton Matthew hold?
Winton Matthew holds: CRVO, INZY stocks.
What was Winton Matthew’s latest transaction?
Winton Matthew latest transaction was an Informative Buy of $41.43K.
What was Winton Matthew's most profitable transaction?
Winton Matthew’s most profitable transaction was an Informative Buy of CRVO stock on November 17, 2025. The return on the trade was -68.80%.
What is Winton Matthew's role in CervoMed?
Winton Matthew's role in CervoMed is Chief Commercial and Business.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.